The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which scientists say could help end the virus' transmission. In a statement on ...

Nigeria faces a critical challenge in halting mother-to-child HIV transmission. Thousands of infants are born with HIV annually. Learn about the systemic failures and potential solutions.

SPOKANE, Wash. – The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the approval, Dr. Rachel Safran was part of an original ...

Chicago, Cook County and Illinois are on the cusp of ending the HIV epidemic in our city, county and state. But that progress is fragile.

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving innovations at risk.

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

FEWER than half of the Jamaicans on antiretroviral treatment (ARTs), aimed at combating the spread of HIV/AIDS, were virally suppressed at the end of last year. This relatively low number (46 per ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a twice-yearly injectable.

As HIV cases continue to rise in the Philippines, especially among the youth, a new global development may offer hope in prevention efforts.

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

So despite the success of HIV drugs and PrEP, precarious health-care systems and high drug costs mean we can’t rely on them to bring an end to the ongoing global HIV pandemic.

Discover what non-reactive HIV test results really mean and why testing timing, window periods, and retesting are crucial for accuracy.